Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

242 11 Hybrid Cell Vaccination for Cancer Immune Therapy
Circulating Melan-A/Mart-1 specific cytolytic
T lymphocyte precursors in
HLA-A2 + melanoma patients have a
memory phenotype. Int J Cancer 1998;
78: 699±706.
13 Romero P, Dunbar PR,Valmori D,
Pittet M, Ogg GS, Rimoldi D,
Chen JL, Lienard D, Cerottini JC,
Cerundolo V. Ex vivo staining of metastatic
lymph nodes by class I major histocompatibility
complex tetramers reveals
high numbers of antigen-experienced
tumor-specific cytolytic T lymphocytes.
J Exp Med 1998; 188: 1641±
50.
14 Romero P, Gervois N, Schneider J,
Escobar P,Valmori D, Pannetier C,
Steinle A,Wolfel T, Lienard D, Brichard
V, van Pel A, Jotereau F, Cerottini
JC. Cytolytic T lymphocyte recognition
of the immunodominant
HLA-A*0201-restricted Melan-A/MART-
1 antigenic peptide in melanoma. JImmunol
1997; 159: 2366±74.
15 Valmori D, Lienard D,Waanders G,
Rimoldi D, Cerottini JC, Romero P.
Analysis of MAGE-3-specific cytolytic T
lymphocytes in human leukocyte antigen-A2
melanoma patients. Cancer Res
1997; 57: 735±41.
16 Zarour H, De Smet C, Lehmann F,
Marchand M, Lethe B, Romero P,
Boon T, Renauld JC. The majority of
autologous cytolytic T-lymphocyte
clones derived from peripheral blood
lymphocytes of a melanoma patient recognize
an antigenic peptide derived
from gene Pmel17/gp100. J Invest Dermatol
1996; 107: 63±7.
17 Romero P. Cytolytic T lymphocyte responses
of cancer patients to tumor-associated
antigens. Springer Semin Immunopathol
1996; 18: 185±98.
18 Gnjatic S, Nagata Y, Jager E, Stockert
E, Shankara S, Roberts BL, Mazzara
GP, Lee SY, Dunbar PR, Dupont
B, Cerundolo V, Ritter G, Chen YT,
Knuth A, Old LJ. Strategy for monitoring
T cell responses to NY-ESO-1 in patients
with any HLA class I allele. Proc
Natl Acad Sci USA 2000; 97: 10917±22.
19 Jager E, Nagata Y, Gnjatic S,Wada H,
Stockert E, Karbach J, Dunbar PR,
Lee SY, Jungbluth A, Jager D,
Arand M, Ritter G, Cerundolo V,
Dupont B, Chen YT, Old LJ, Knuth A.
Monitoring CD8 T cell responses to NY-
ESO-1: correlation of humoral and cellular
immune responses. Proc Natl
Acad Sci USA 2000; 97: 4760±5.
20 Romero P, Dunbar PR,Valmori D,
Pittet M, Ogg GS, Rimoldi D,
Chen JL, Lienard D, Cerottini JC,
Cerundolo V. Ex vivo staining of metastatic
lymph nodes by class I major histocompatibility
complex tetramers reveals
high numbers of antigen-experienced
tumor-specific cytolytic T lymphocytes.
J Exp Med 1998; 188: 1641±
50.
21 Ogg GS, Rod Dunbar P, Romero P,
Chen JL, Cerundolo V. High frequency
of skin-homing melanocyte-specific
cytotoxic T lymphocytes in autoimmune
vitiligo. J Exp Med 1998; 188:
1203±8.
22 Anichini A, Molla A, Mortarini R,
Tragni G, Bersani I, Di Nicola M,
Gianni AM, Pilotti S, Dunbar R,
Cerundolo V, Parmiani G. An expanded
peripheral T cell population to a
cytotoxic T lymphocyte (CTL)-defined,
melanocyte-specific antigen in metastatic
melanoma patients impacts on
generation of peptide-specific CTLs but
does not overcome tumor escape from
immune surveillance in metastatic lesions.
J Exp Med 1999; 190: 651±67.
23 Valmori D, Pittet MJ,Vonarbourg C,
Rimoldi D, Lienard D, Speiser D,
Dunbar R, Cerundolo V, Cerottini
JC, Romero P. Analysis of the cytolytic
T lymphocyte response of melanoma
patients to the naturally HLA-
A*0201-associated tyrosinase peptide
368±376. Cancer Res 1999; 59: 4050±5.
24 Schuler-Thurner B, Dieckmann D,
Keikavoussi P, Bender A, Maczek C,
Jonuleit H, Roder C, Haendle I,
Leisgang W, Dunbar R, Cerundolo
V, von Den Driesch P, Knop J,
Brocker EB, Enk A, Kampgen E,
Schuler G. Mage-3 and influenza-matrix
peptide-specific cytotoxic T cells are
inducible in terminal stage HLA-A2.1 +
melanoma patients by mature monocyte-derived
dendritic cells. J Immunol
2000; 165: 3492±6.